. 2021 Jun 29;12(8):1245–1252. doi: 10.1021/acsmedchemlett.1c00032

Table 3. Antiproliferative Activity of 12, 16, 18–20, and 26–29 in the VCaP Prostate Cancer Cell Line Compared with That of 1 and 4^a.

compound	1	4	12	16	18	19	20	(S)-26	(S)-27	(R)-28	(R)-29
VCaP IC₅₀ (nM)	149 ± 30	92 ± 71	2440 ± 2010	40 ± 40	30 ± 20	50 ± 20	10 ± 10	680 ± 150	480 ± 50	40 ± 10	110 ± 30

VCaP cells (WT AR) were cultured in the presence of 30 pM R1881, and the extent of androgen-dependent proliferation was calculated. The VCaP antiproliferative assay was repeated two times or more.

Table 3. Antiproliferative Activity of 12, 16, 18–20, and 26–29 in the VCaP Prostate Cancer Cell Line Compared with That of 1 and 4a.

Table 3. Antiproliferative Activity of 12, 16, 18–20, and 26–29 in the VCaP Prostate Cancer Cell Line Compared with That of 1 and 4^a.